ClinicalTrials.gg
Not yet recruitingNCT07940777SOLSTICE-HCMUpdated Nov 17, 2026

A Study to Evaluate the Safety and Efficacy of Mavacamten in Adults With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy (SOLSTICE-HCM)

A Phase 3 interventional study of Mavacamten and Placebo in Non-obstructive Hypertrophic Cardiomyopathy, sponsored by Bristol-Myers Squibb. Not yet recruiting. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Primary conditionCardiomyopathy, HypertrophicRegistry: CardiomyopathiesReclassifiedWhy we changed it
Registry
Cardiomyopathies — the first condition term the registry derived for this study.
ClinicalTrials.gg
Cardiomyopathy, Hypertrophic
Why
  1. The study's listed conditions name Cardiomyopathy, Hypertrophic, a narrower term within Cardiomyopathies.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb — 10 open to participants now, 15 under way, 2 of them phase 3. Cardiomyopathy, Hypertrophic · Bristol-Myers Squibb.

Planned enrollment
2nd of 17
500 · median 59
Started
2026
with 4 others
Phase 3
6 of 32
1 open now
Primary completion
2029-07
later than 12 of 14 live
Registered
32nd of 32
by date

Among the 32 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb, this one is the 2nd largest by planned enrollment of the 17 interventional ones that give a count, is one of 5 that started in 2026, is one of 6 in phase 3, reaches primary completion later than 12 of the 14 other live ones, and was the 32nd registered.

Cardiomyopathy, Hypertrophic

363 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 116 are open to participants now.

Browse Cardiomyopathy, Hypertrophic studies →

Open to participants now

10 of the 32 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Who these studies take

Of the 81 Cardiomyopathy, Hypertrophic studies recruiting now, 55 (68%) set no upper age limit and 8 (10%) stop at 75 or younger; 21 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Cardiomyopathy, Hypertrophic by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

A study to evaluate the safety and efficacy of Mavacamten in adults with Symptomatic Non-obstructive Hypertrophic Cardiomyopathy (SOLSTICE-HCM)

03

Conditions studied

  • Non-obstructive Hypertrophic Cardiomyopathy

Browse trials for

Keywords

  • Cardiomyopathy
  • Hypertrophic cardiomyopathy
  • Non-obstructive cardiomyopathy.
04

In context

Cardiomyopathy, Hypertrophic Reclassified

363 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 116 are open to participants now.

This study's planned enrollment of 500 is above the median of 60 across 180 interventional studies indexed under Cardiomyopathy, Hypertrophic.

Browse Cardiomyopathy, Hypertrophic studies →

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,562 studies on the registry; 119 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Compared within Cardiomyopathy, Hypertrophic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Cardiomyopathies. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have unexplained left-ventricular hypertrophy with non-dilated ventricular chambers in the absence of other cardiac or systemic disease which can produce the required magnitude of hypertrophy of a maximal LV wall thickness ≥ 15 mm (or ≥ 13 mm with positive family history of hypertrophic cardiomyopathy [HCM] or an identified pathogenic or likely pathogenic variant on genetic testing)
  • Participants must have left ventricular systolic function meeting protocol specified requirements on screening echocardiography
  • Participants must have KCCQ-23 CSS within the protocol-specified range at screening

Exclusion criteria

Exclusion Criteria:

  • Participants must not have known infiltrative or storage disorder causing an increase in wall thickness that can mimic nHCM, such as amyloidosis, Fabry disease, Noonan syndrome, or glycogen storage disease.
  • Participants must not have any history of left ventricular systolic dysfunction, as defined in the protocol, prior to screening and up to the time of randomization
  • Other protocol-defined inclusion/exclusion criteria apply.
06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
500 participants (estimated)

Study arms

  • Experimental
    Arm A

    Drug: Mavacamten

  • Experimental
    Arm B

    Drug: Mavacamten · Other: Placebo

Interventions

  • DrugMavacamten

    Specified dose on specified days

  • OtherPlacebo

    Specified dose on specified days

07

What researchers measure

Primary outcomes

  1. Change from baseline in Peak Oxygen Consumption (pVO2)

    Time frame: At Week 48

  2. Change from baseline in Kansas City Cardiomyopathy Questionnaire, 23-item (KCCQ-23 CSS)

    Time frame: At Week 48

Secondary outcomes

  1. Change from Baseline in Composite Z-score of Cardiopulmonary Exercise Testing (CPET) Parameters (pVO₂ and Ventilatory Efficiency (VE/VCO₂) Slope)

    Time frame: At Week 48

  2. Change from baseline in N-terminal Pro B-type Natriuretic Peptide (NT-proBNP)

    Time frame: At Week 48

  3. Number of participants with at least 1 class of New York Heart Association (NYHA) improvement from baseline

    Time frame: At Week 48

  4. Change from baseline in Hypertrophic Cardiomyopathy Symptom Questionnaire (HCMSQ) Shortness of Breath (SoB)

    Time frame: At Week 48

08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.bms.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Jul 2029, 30 months later.

Of 15 phase 3 interventional studies under Cardiomyopathy, Hypertrophic, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 36. This study's planned 30 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2026
First posted
Nov 17, 2026
StartEst.
Dec 29, 2026
Primary completionEst.
Jul 21, 2029
CompletionEst.
Jul 19, 2032
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07940777
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Dec 29, 2026 (estimated)
Primary completion
Jul 21, 2029 (estimated)
Completion
Jul 19, 2032 (estimated)
Last update
Nov 17, 2026

Study contacts

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
Contact
Clinical.Trials@bms.com
855-907-3286
First line of the email MUST contain NCT # and Site #.
Contact
Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion